drugset / Trial / NCT00216541

A Study of the Safety and Effectiveness of Epoetin Alfa on Hemoglobin Levels and Blood Transfusions in Cancer Patients Receiving Chemotherapy

NCT00216541

Phase 4 Completed 110 enrolled Janssen-Cilag B.V.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effect of early treatment with epoetin alfa in addition to best standard of care on hemoglobin levels and the need for red blood cell transfusions in cancer patients receiving chemotherapy as compared to patients receiving standard epoetin alfa treatment and best standard of care.

Timeline

Start
2003-08
Primary completion
Completion
2006-09

Drugs

EvaluationDrugModalityDoseRoute
Subject epoetin alfa Protein / enzyme biologic 40000 iu Subcutaneous

Indications